Nirsevimab (secondary prophylaxis of RSV lower respiratory tract disease) - Addendum to Project A24-27

Report documents

1. Addendum

   Nirsevimab (secondary prophylaxis of RSV lower respiratory tract disease) - Addendum to Project A24-27

   published on

   15.08.2024

   Document type

   PDF document, 268 kB, EN, not accessible

   DOI-Link

   https://doi.org/10.60584/A24-75_en

   Download file : Addendum (PDF document, 268 kB, EN, not accessible)

Additional information

Project details

Project no.

A24-75

Commission

Commission awarded on 09.07.2024 by the Federal Joint Committee (GBA).

Report type

Addendum

Status

Commission completed

Department/Division

Drug Assessment

Topic

Immune system and infections

Note

If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.

DOI

https://doi.org/10.60584/A24-75_en

Connected Projects

1. Dossier assessment

   Nirsevimab (prevention of RSV disease) – Benefit assessment according to §35a Social Code Book V

   Project no.

   A24-27

   Last updated

   15.08.2024

   Status: Commission completed